Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

G8048

Sigma-Aldrich

GLP-1R agonist

≥98% (HPLC), powder, glucose homeostasis regulator

Sinónimos:

2-Quinoxalinamine, 6,7-dichloro-N-(1,1-dimethylethyl)-3-(methylsulfonyl)-, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), Compound 2

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C13H15Cl2N3O2S
Número de CAS:
281209-71-0
Peso molecular:
348.25
UNSPSC Code:
12352200
NACRES:
NA.77

product name

GLP-1R agonist, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

light brown-yellow

solubility

DMSO: ≥10 mg/mL

storage temp.

2-8°C

InChI

1S/C13H15Cl2N3O2S/c1-13(2,3)18-11-12(21(4,19)20)17-10-6-8(15)7(14)5-9(10)16-11/h5-6H,1-4H3,(H,16,18)

InChI key

GNZCSGYHILBXLL-UHFFFAOYSA-N

General description

Glucagon-like peptide-1 receptor (GLP-1R) agonist is a potential oral drug for modulating glucagon-like peptide (GLP)-1 in diabetic patients. GLP-1R agonists play a key role in lowering glycated hemoglobin levels. It improves glycemic control and maintenance of body weight.

Biochem/physiol Actions

GLP-1R is a small molecule GLP-1 receptor agonist. GLP-1 receptor signaling is a predominant mechanism for regulating glucose homeostasis. This compound represents a unique non-peptide tool for studying the role of GLP-1 in both in vivo and in vitro diabetes and obesity models.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

GLP-1 receptor agonists: a review of head-to-head clinical studies.
Trujillo JM, et al.
Therapeutic advances in endocrinology and metabolism, 6(1), 19-28 (2015)
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
Garber AJ.
Diabetes Care, 34(Supplement 2), S279-S284 (2011)
Juliana de F Germano et al.
Scientific reports, 10(1), 8284-8284 (2020-05-20)
Given that adverse remodeling is the leading cause of heart failure and death in the USA, there is an urgent unmet need to develop new methods in dealing with this devastating disease. Here we evaluated the efficacy of a short-course
Small-molecule agonists for the glucagon-like peptide 1 receptor.
Knudsen LB, et al.
Proceedings of the National Academy of Sciences of the USA, 104(3), 937-942 (2007)
Juliana de Freitas Germano et al.
International journal of molecular sciences, 22(16) (2021-08-28)
Cardiovascular disease is the main cause of death worldwide, making it crucial to search for new therapies to mitigate major adverse cardiac events (MACEs) after a cardiac ischemic episode. Drugs in the class of the glucagon-like peptide-1 receptor agonists (GLP1Ra)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico